Quadrature Capital Ltd Buys Shares of 71,113 Indivior PLC (NASDAQ:INDV)

Quadrature Capital Ltd acquired a new stake in Indivior PLC (NASDAQ:INDV) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 71,113 shares of the company’s stock, valued at approximately $1,523,000.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Indivior by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock valued at $90,081,000 after buying an additional 52,836 shares during the period. Norges Bank acquired a new stake in shares of Indivior in the fourth quarter valued at $36,011,000. Toronto Dominion Bank boosted its holdings in Indivior by 58.0% in the first quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock valued at $44,872,000 after purchasing an additional 769,000 shares during the period. Premier Fund Managers Ltd grew its stake in Indivior by 17.8% during the 4th quarter. Premier Fund Managers Ltd now owns 850,980 shares of the company’s stock worth $12,901,000 after purchasing an additional 128,611 shares in the last quarter. Finally, UBS Group AG grew its stake in Indivior by 71.9% during the 4th quarter. UBS Group AG now owns 826,130 shares of the company’s stock worth $12,615,000 after purchasing an additional 345,556 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Stock Down 2.3 %

Shares of INDV stock traded down $0.30 on Friday, reaching $12.79. 1,487,673 shares of the stock were exchanged, compared to its average volume of 920,827. Indivior PLC has a twelve month low of $9.14 and a twelve month high of $24.11. The company has a current ratio of 0.92, a quick ratio of 0.74 and a debt-to-equity ratio of 23.50. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of 1,279.00 and a beta of 0.69. The business’s 50 day moving average price is $15.09 and its 200 day moving average price is $17.65.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, April 25th. The company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.01). Indivior had a negative return on equity of 4,735.71% and a negative net margin of 12.29%. The business had revenue of $284.00 million for the quarter, compared to analyst estimates of $300.00 million. As a group, sell-side analysts expect that Indivior PLC will post 1.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

INDV has been the subject of several recent research reports. Piper Sandler started coverage on Indivior in a research note on Tuesday. They issued an “overweight” rating and a $22.00 price objective for the company. Craig Hallum reduced their target price on shares of Indivior from $37.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday, July 10th.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.